SecBot SecBot
8-K ·Filed Sep 3, 2026

PROF

Profound Medical Corp.
NEUTRAL
Impact 3/10
Horizonweeks Processed2mo ago SEC0001171843-26-005868
8-K context-dependent: Items 5.02, 7.01
Actionable Insight • Neutral

Monitor for any strategic shifts under Fabian's commercial leadership, particularly around TULSA-PRO adoption and Sonalleve expansion. The next quarterly earnings call will be the first opportunity to gauge execution changes.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$6.80
T+0 close · Sep 3, 2026 · via day close
Latest settled
−14.12%
T+20 · $5.84 · next T+60 in 13d
Vs SPY
−12.93%
α at T+20
Latest observation
+17.03%
T+49 · FF3 residual α
  1. T+0 · Sep 3 $6.80entry
  2. T+1 · 2mo ago +1.32%α +1.71% · $6.89
  3. T+5 · 2mo ago −12.21%α −11.06% · $5.97
  4. T+20 · 7w ago −14.12%α −12.93% · $5.84
  5. T+51 · todayOpen
  6. T+60 · in 13d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Profound Medical appointed Richard Fabian as President, effective September 1, 2026, succeeding Mathieu Burtnyk who moved to the newly created Chief Technology Officer role. Fabian brings deep medical device and imaging leadership from FUJIFILM Sonosite and Philips Healthcare. This is a routine executive restructuring with no financial data or guidance provided, making it a neutral event for traders.

Key Facts

  • Richard Fabian appointed President effective September 1, 2026
  • Mathieu Burtnyk shifted to newly created Chief Technology Officer role
  • Fabian previously President and CEO of FUJIFILM Sonosite (2017-2026) and held executive roles at Philips Healthcare
  • Employment agreement: $550,000 annual base salary, up to 100% bonus, 200,000 RSUs (3-year vest), options for 475,000 shares (4-year vest)
  • Company will lease a Toronto residence for Fabian during initial 12 months
  • No financial results, guidance, or material operational updates disclosed

Financial Impact

No financial impact disclosed, executive appointment only

Risk Factors

  • No financial data or guidance provided, limited trading signal
  • Executive transition risk if Fabian's commercial focus diverges from prior R&D-driven strategy

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
80% bullish (5 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001171843-26-005868
Exhibit: exh_991.htm0001171843-26-005868
Document: 0001171843-26-005868-index-headers.html0001171843-26-005868
Document: 0001171843-26-005868-index.html0001171843-26-005868
Document: 0001171843-26-005868.txt0001171843-26-005868

US Market Status

Market Closed · Opens Wed (9h 59m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 3, 2026